• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Social Work Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
    • Psychiatry News Videos
    • Medication Guide Videos
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • FAQs
  • Med Fact Book App
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Brexpiprazole Ineffective in Mania

Brexpiprazole Ineffective in Mania

September 28, 2021
Richard Moldawsky, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Richard Moldawsky, MD. Dr. Moldawsky has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

REVIEW OF: Vieta E et al, J Psychopharmacol 2021;35(8):971–982


TYPE OF STUDY: Phase III randomized controlled trials


Brexpiprazole is FDA approved in schizophrenia and as an adjunct for major depression and is one of the better-tolerated antipsychotics. Like aripiprazole, it is a partial D2 and 5-HT1A agonist. Unlike most antipsychotics, brexpiprazole has never been studied in acute mania, so these two recently published industry-sponsored trials give us the first glimpse of its antimanic potential.


The trials employed similar designs. Both were large, randomized, placebo-controlled trials that compared brexpiprazole with placebo over three weeks in acute bipolar I mania. The participants were drawn from US and European sites and had a Young Mania Rating Scale (YMRS) score over 24 at entry. Brexpiprazole was started at 2 mg/day and titrated up to 4 mg/day as tolerated. No other medication was allowed except lorazepam on an as-needed basis. The trials enrolled 654 patients, over 75% of whom completed the acute phase.


After three weeks, YMRS scores were about the same for drug and placebo, although the brexpiprazole group scored a little better on the secondary Clinical Global Impression—Bipolar Disorder (CGI-BD) measure.


Both trials included an open-label, long-term phase where symptoms were treated with brexpiprazole for another six months if the investigators thought patients would benefit from continued treatment. Outcome measures over the 26 weeks of this phase showed gradual decreases in YMRS and CGI-BD scores, but the changes were not dramatic and there was no control arm to compare them to.


Brexpiprazole was well tolerated, with akathisia the most commonly reported adverse effect. During the open-label extension, six patients became manic, five became depressed, and four developed suicidal ideation, but these events lacked a placebo arm for comparison.


The multicenter design may have obscured the drug-placebo difference. There are more investigators per patient in multicenter trials, increasing the attention each patient receives and amplifying the placebo effect. However, other antipsychotics have overcome this and yielded positive results in mania during multicenter trials.


The authors conducted a secondary analysis in an attempt to salvage some signal of response in these patients. Based on earlier evidence that poor insight predicts a better response to antipsychotics in mania (Welten CCM et al, J Clin Psychopharmacol 2016;36(1):71–76), they reanalyzed the data and found that poorer insight was associated with a statistically significant improvement on brexpiprazole relative to placebo (odds ratio 2.2, CI 1.1–4.4).


TCPR’s Take
The atypical antipsychotics are a varied class, and we can’t conclude all of them work in acute mania. Stick with those that are FDA approved in mania (aripiprazole, asenapine, cariprazine, olanzapine, quetiapine, risperidone, and ziprasidone), as the others in this class are either untested (eg, lumateperone, lurasidone) or have negative results in this condition (eg, paliperidone).

General Psychiatry
KEYWORDS brexpiprazole mania mood_stabilizers psychopharm-myths psychopharmacology research-update
    Richard Moldawsky, MD.

    Quetiapine in Bipolar With OCD

    More from this author
    www.thecarlatreport.com
    Issue Date: September 28, 2021
    SUBSCRIBE NOW
    Table Of Contents
    The Schizophrenia-OCD Overlap
    Light Therapy: Good for What Ails You?
    How to Diagnose ADHD in Bipolar Disorder
    Brexpiprazole Ineffective in Mania
    Omega-3s and Metabolic Risks in Schizophrenia
    CME Post-Test - Mood Disorder, TCPR, October 2021
    DOWNLOAD NOW
    Featured Book
    • MFB7e_Print_App_Access.png

      Medication Fact Book for Psychiatric Practice, Seventh Edition (2024) - Regular Bound Book

      The updated 2024 reference guide covering the most commonly prescribed medications in psychiatry.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2622607431.jpg
      General Psychiatry

      Should You Test MTHFR?

      MTHFR is a...
      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2025 Carlat Publishing, LLC and Affiliates, All Rights Reserved.